Active Microneedle Administration of Plant Virus Nanoparticles for Cancer In Situ Vaccination Improves Immunotherapeutic Efficacy

Christine E. Boone,Chao Wang,Miguel Angel Lopez-Ramirez,Veronique Beiss,Sourabh Shukla,Paul L. Chariou,Daniel Kupor,Ricardo Rueda,Joseph Wang,Nicole F. Steinmetz

DOI: https://doi.org/10.1021/acsanm.0c01506

IF: 6.14

2020-08-07

ACS Applied Nano Materials

Abstract:The solid tumor microenvironment (TME) poses a significant structural and biochemical barrier to immunotherapeutic agents. To address the limitations of tumor penetration and distribution and to enhance antitumor efficacy of immunotherapeutics, we present here an autonomous active microneedle (MN) system for the direct intratumoral (IT) delivery of a potent immunoadjuvant, cowpea mosaic virus nanoparticles (CPMV), in vivo. In this active delivery system, magnesium (Mg) microparticles embedded into active MNs react with the interstitial fluid in the TME, generating a propulsive force to drive the nanoparticle payload into the tumor. Active delivery of the CPMV payload into B16F10 melanomas in vivo demonstrated substantially more pronounced tumor regression and prolonged survival of tumor-bearing mice compared to that of passive MNs and conventional needle injection. Active MN administration of CPMV also enhanced local innate and systemic adaptive antitumor immunity. Our approach represents an elaboration of conventional CPMV in situ vaccination, highlighting substantial immune-mediated antitumor effects and improved therapeutic efficacy that can be achieved through CPMV in situ vaccination mediated by an active and autonomous delivery system.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsanm.0c01506?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsanm.0c01506</a>.(Figure S1) CPMV in situ vaccination administered by passive microneedle (MN) patches in the B16F10 dermal melanoma model; (Figure S2) Cy5-CPMV loaded active and passive MN characterization; (Figure S3) intratumoral innate immune cell profile following CPMV microneedle administration; (Figure S4) CIE diagrams showing the gating strategy for detection of CD44^hiIFN-γ⁺CD8⁺ T cells by the splenocyte interferon gamma release assay (<a class="ext-link" href="/doi/suppl/10.1021/acsanm.0c01506/suppl_file/an0c01506_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

materials science, multidisciplinary,nanoscience & nanotechnology

What problem does this paper attempt to address?

This paper aims to address the significant structural and biochemical barriers formed by the tumor microenvironment (TME) to the penetration and distribution of immunotherapeutic drugs. Specifically, the paper proposes an autonomous active microneedle (MN) system for the direct in vivo delivery of a potent immunoadjuvant—cowpea mosaic virus nanoparticles (CPMV)—into tumors. This method generates propulsion by reacting magnesium (Mg) microparticles with the interstitial fluid in the TME, thereby propelling the nanoparticle payload into the tumor interior. The study found that, compared to passive microneedles and traditional needle injections, this active microneedle delivery of CPMV significantly promotes tumor regression and extends the survival time of mice bearing melanoma. Additionally, this method enhances both local innate and systemic adaptive antitumor immune responses. Therefore, this research demonstrates the potential of CPMV in situ vaccination achieved through an active autonomous delivery system to improve the efficacy of immunotherapy.